Edited by Ganapathy Subramanian

# Process Control, Intensification, and Digitalisation in Continuous Biomanufacturing



Process Control, Intensification, and Digitalisation in Continuous Biomanufacturing

# Process Control, Intensification, and Digitalisation in Continuous Biomanufacturing

Edited by Ganapathy Subramanian

# WILEY-VCH

#### Editor

# Dr. Ganapathy Subramanian

44 Oaken Grove SL6 6HH Maidenhead, Berkshire United Kingdom

Cover Image: © icestylecg/Getty Images

All books published by **WILEY-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

**British Library Cataloguing-in-Publication Data** A catalogue record for this book is available from the British Library.

# Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2022 WILEY-VCH GmbH, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-34769-8 ePDF ISBN: 978-3-527-82732-9 ePub ISBN: 978-3-527-82733-6 oBook ISBN: 978-3-527-82734-3

Typesetting Straive, Chennai, India

Printed on acid-free paper

 $10 \hspace{0.15cm} 9 \hspace{0.15cm} 8 \hspace{0.15cm} 7 \hspace{0.15cm} 6 \hspace{0.15cm} 5 \hspace{0.15cm} 4 \hspace{0.15cm} 3 \hspace{0.15cm} 2 \hspace{0.15cm} 1$ 

# Contents

Preface xiii

# Part I Continuous Biomanufacturing 1

v

1	Strategies for Continuous Processing in Microbial Systems 3
	Julian Kopp, Christoph Slouka, Frank Delvigne, and Christoph Herwig
1.1	Introduction 3
1.1.1	Microbial Hosts and Their Applications in Biotechnology 3
1.1.2	Regulatory Demands for Their Applied Cultivation Mode 5
1.2	Overview of Applied Cultivation Methods in Industrial
	Biotechnology 6
1.2.1	Batch and Fed-Batch Cultivations 7
1.2.1.1	Conventional Approaches and Their Technical Limitations 7
1.2.1.2	Feeding and Control Strategies Using <i>E. coli</i> as a Model Organism 8
1.2.2	Introduction into Microbial Continuous Biomanufacturing (CBM) 9
1.2.2.1	General Considerations 9
1.2.2.2	Mass Balancing and the Macroscopic Effects in Chemostat Cultures 11
1.2.3	Microbial CBM vs. Mammalian CBM 13
1.2.3.1	Differences in Upstream of Microbial CBM Compared with Cell
	Culture 13
1.2.3.2	Downstream in Microbial CBM 14
1.3	Monitoring and Control Strategies to Enable CBM with Microbials 16
1.3.1	Subpopulation Monitoring and Possible PAT Tools Applicable for
	Microbial CBM 16
1.3.2	Modeling and Control Strategies to Enable CBM with Microbials 19
1.4	Chances and Drawbacks in Continuous Biomanufacturing with
	E. coli 21
1.4.1	Optimization of Plant Usage Using CBM with E. coli 21
1.4.2	Reasons Why CBM with E. coli Is Not State of the Art (Yet) 23
1.4.2.1	Formation of Subpopulation Following Genotypic Diversification 23
1.4.2.2	Formation of Subpopulation Following Phenotypic Diversification 25

vi Contents

1.4.2.3	Is Genomic Integration of the Target Protein an Enabler for CBM with				
1 4 2	E. coli? 26				
1.4.3	Solutions to Overcome the Formation of Subpopulations and How to				
15	Conclusion and Outlook 20				
1.5	Peferences 30				
	References 50				
2	Control of Continuous Manufacturing Processes for Production				
	of Monoclonal Antibodies 39				
	Anurag S. Rathore, Garima Thakur, Saxena Nikita, and Shantanu Banerjee				
2.1	Introduction 39				
2.2	Control of Upstream Mammalian Bioreactor for Continuous Production				
23	Integration Between Unstream and Downstream in Continuous				
2.5	Production of mAbs 46				
2.3.1	Continuous Clarification as a Bridge Between Continuous Upstream and				
	Downstream 46				
2.3.2	Considerations for Process Integration 48				
2.4	Control of Continuous Downstream Unit Operations in mAb				
	Manufacturing 49				
2.4.1	Control of Continuous Dead-End Filtration 49				
2.4.2	Control of Continuous Chromatography 50				
2.4.3	Control of Continuous Viral Inactivation 53				
2.4.4	Control of Continuous Precipitation 54				
2.4.5	Control of Continuous Formulation 56				
2.5	Integration Between Adjacent Unit Operations Using Surge Tanks 57				
2.6	Emerging Approaches for High-Level Monitoring and Control of				
	Continuous Bioprocesses 59				
2.6.1	Artificial Intelligence (AI) and Machine Learning (ML) Control 60				
2.6.2	Statistical Process Control 61				
2.6.3	Process Digitalization 62				
2.7	Conclusions 63				
	References 63				
3	Artificial Intelligence and the Control of Continuous				
	Manufacturing 75				
	Steven S. Kuwahara				
3.1	Introduction 75				
3.2	Continuous Monitoring and Validation 84				
3.3	Choosing Other Control Charts 84				
3.4	Information Awareness 85				
3.5	Management and Personnel 86				
	References 90				

	· ····································
4	<b>Bioprocess Intensification: Technologies and Goals</b> 95 William G. Whitford
4.1	Introduction 95
4.2	Bioprocess Intensification 98
4.2.1	Definition 98
4.2.2	New Directions 100
4.2.3	Sustainability Synergy 102
4.3	Intensification Techniques 103
4.3.1	Enterprise Resource Management 103
4.3.2	Synthetic Biology and Genetic Engineering 104
4.3.3	New Expression Systems 105
4.3.4	Bioprocess Optimization 106
4.3.5	Bioprocess Simplification 107
4.3.6	Continuous Bioprocessing 108
4.4	Materials 109
4.4.1	Media Optimization 109
4.4.2	Variability 110
4.5	Digital Biomanufacturing 110
4.5.1	Data 111
4.5.2	Bioprocess Control 112
4.5.3	Digital Twins 113
4.5.4	Artificial Intelligence 114
4.5.5	Cloud/Edge Computing 114
4.6	Bioprocess Modeling 114
4.7	Automation and Autonomation 115
4.8	Bioprocess Monitoring 117
4.9	Improved Process and Product Development 118
4.9.1	Design of Experiments 118
4.9.2	QbD and PAT 119
4.9.3	High-Throughput Systems 119
4.9.4	Methods 120
4.9.5	Commercialized Systems 120
4.10	Advanced Process Control 121
4.11	Bioreactor Design 121
4.12	Single-Use Systems 122
4.13	Facilities 123
4.14	Conclusion 126
	Abbreviations and Acronyms 126
	Acknowledgment 129
	References 129

### Part II Intensified Biomanufacturing 93

viii Contents

5	Process Intensification Based on Disposable Solutions as First			
	Step Toward Continuous Processing 137			
	Stefan R. Schmidt			
5.1	Introduction 137			
5.1.1	Theory and Practice of Process Intensification 137			
5.1.2	Current Bioprocessing 140			
5.1.3	General Aspects of Disposables 140			
5.2	Technical Solutions 141			
5.2.1	Process Development 141			
5.2.2	Upstream Processing Unit Operations 142			
5.2.2.1	High-Density, Large-Volume Cell Banking in Bags 143			
5.2.2.2	Seed Train Intensification 144			
5.2.2.3	Cell Retention and Harvest 145			
5.2.3	Downstream Processing Unit Operations 149			
5.2.3.1	Depth Filtration 149			
5.2.3.2	In-line Virus Inactivation 151			
5.2.3.3	In-line Buffer Blending and Dilution 152			
5.2.3.4	Chromatography 153			
5.2.3.5	Tangential Flow Filtration 159			
5.2.3.6	Drug Substance Freezing 161			
5.3	Process Analytical Technology and Sensors 162			
5.3.1	Sensors for USP Applications 163			
5.3.2	Sensors for DSP Applications 164			
5.4	Conclusions 165			
5.4.1	Transition from Traditional to Intensified Processes 165			
5.4.2	Impact on Cost 169			
5.4.3	Influence on Time 170			
	References 171			
6	Single-Use Continuous Manufacturing and Process			
	Intensification for Production of Affordable Biological			
	Drugs 179			
	Ashish K. Joshi and Sanjeev K. Gupta			
6.1	Background 179			
6.2	State of Upstream and Downstream Processes 180			
6.2.1	Sizing Upstream Process 181			
6.2.2	Sizing Downstream Process 182			
6.2.3	Continuous Process Retrofit into the Existing Facility 184			
6.2.3.1	Upstream Process 184			
6.2.3.2	Downstream Process 184			
6.2.4	Learning from Chemical Industry 185			
6.3	Cell Line Development and Manufacturing Role 186			
6.3.1	Speeding Up Upstream and Downstream Development 188			
6.3.2	The State of Manufacturing 189			
6.4	Process Integration and Intensification 190			

- 6.4.1 Intensification of a Multiproduct Perfusion Platform 190
- 6.4.2 Upstream Process Intensification Using Perfusion Process 192
- 6.5 Process Intensification and Integration in Continuous Manufacturing 192
- 6.6 Single-Use Manufacturing to Maximize Efficiency 194
- 6.6.1 The Benefits of SUT in the New Era of Biomanufacturing 195
- 6.6.2 Managing an SUT Cost Profile 195
- 6.6.3 In-Line Conditioning (ILC) 196
- 6.6.4 Impact of Single-Use Strategy on Manufacturing Cost of Goods 197
- 6.6.5 Limitations of SUT 198
- 6.7 Process Economy 199
- 6.7.1 Biopharma Market Dynamics 200
- 6.7.2 Management of the Key Risks of a Budding Market 201
- 6.8 Future Perspective 202 References 203

Part III Digital Biomanufacturing 209

### 7 Process Intensification and Industry 4.0: Mutually Enabling Trends 211

Marc Bisschops and Loe Cameron

- 7.1 Introduction 211
- 7.2 Enabling Technologies for Process Intensification 213
- 7.2.1 Process Intensification in Biomanufacturing 213
- 7.2.2 Process Intensification in Cell Culture 214
- 7.2.3 Process Intensification in Downstream Processing 214
- 7.2.4 Process Integration: Manufacturing Platforms 216
- 7.2.5 The Two Elephants in the (Clean) Room 217
- 7.3 Digital Opportunities in Process Development 220
- 7.4 Digital Opportunities in Manufacturing 222
- 7.5 Digital Opportunities in Quality Assurance 223
- 7.6 Considerations 224
- 7.6.1 Challenges 224
- 7.6.2 Gene Therapy *226*
- 7.7 Conclusions 227
  - References 227

# 8 Consistent Value Creation from Bioprocess Data with Customized Algorithms: Opportunities Beyond Multivariate Analysis 231

Harini Narayanan, Moritz von Stosch, Martin F. Luna, M.N. Cruz Bournazou, Alessandro Buttè, and Michael Sokolov

- 8.1 Motivation 231
- 8.2 Modeling of Process Dynamics 232

#### **x** Contents

- 8.2.1 Hybrid Models 234
- 8.2.2 Conclusion 238
- 8.3 Predictive Models for Critical Quality Attributes 238
- 8.3.1 Historical Product Quality Prediction 238
- 8.3.2 Synergistic Prediction of Process and Product Quality 242
- 8.4 Extrapolation and Process Optimization 242
- 8.5 Bioprocess Monitoring Using Soft Sensors 247
- 8.5.1 Static Soft Sensor 248
- 8.5.2 Dynamic Soft Sensors 250
- 8.5.3 Concluding Remarks 251
- 8.6 Scale-Up and Scale-Down 251
- 8.6.1 Differences Between Lab and Manufacturing Scales 252
- 8.6.2 Scale-Up 253
- 8.6.3 Scale-Down 254
- 8.6.4 Conclusions 255
- 8.7 Digitalization as an Enabler for Continuous Manufacturing 255 References 257

9 Digital Twins for Continuous Biologics Manufacturing 265

Axel Schmidt, Steffen Zobel-Roos, Heribert Helgers, Lara Lohmann, Florian Vetter, Christoph Jensch, Alex Juckers, and Jochen Strube

- 9.1 Introduction 265
- 9.2 Digital Twins in Continuous Biomanufacturing 269
- 9.2.1 USP Fed Batch and Perfusion 273
- 9.2.2 Capture, LLE, Cell Separation, and Clarification 273
- 9.2.2.1 Fluid Dynamics (Red) 277
- 9.2.2.2 Phase Equilibrium (Blue) 277
- 9.2.2.3 Kinetics (Green) 277
- 9.2.3 UF/DF, SPTFF for Concentration, and Buffer Exchange 278
- 9.2.4 Precipitation/Crystallization 282
- 9.2.5 Chromatography and Membrane Adsorption 282
- 9.2.5.1 General Rate Model Chromatography 282
- 9.2.5.2 SEC 284
- 9.2.5.3 Adsorption Mechanism 284
- 9.2.5.4 IEX-SMA 284
- 9.2.5.5 HIC-SMA 285
- 9.2.5.6 Modified Mixed-Mode SMA 285
- 9.2.5.7 Modified HIC-SMA Process Model Exemplification by mab Purification 287
- 9.2.5.8 Model Parameter Determination 289
- 9.2.5.9 Phase Equilibrium Isotherms 290
- 9.2.5.10 Mass Transfer Kinetics 292
- 9.2.6 Lyophilization 293
- 9.2.6.1 Thermal Conductivity of the Vial 293
- 9.2.6.2 Product Resistance 293

- 9.2.6.3 Product Temperature 295
- 9.2.6.4 Water Properties 295
- 9.3 Process Integration and Demonstration 295
- 9.3.1 USP Fed Batch and Perfusion 301
- 9.3.2 Capture, LLE, Cell Separation, and Clarification 306
- 9.3.3 UF/DF, SPTFF for Concentration, and Buffer Exchange 309
- 9.3.4 Precipitation/Crystallization 311
- 9.3.5 Chromatography and Membrane Adsorption 314
- 9.3.6 Lyophilization 314
- 9.3.7 Comparison Between Conceptual Process Design and Experimental Data *319*
- 9.4 PAT in Continuous Biomanufacturing 320
- 9.4.1 State-of-the-Art PAT 321
- 9.4.2 QbD-based PAT Control Strategy 322
- 9.4.3 Process Simulation Toward APC-Based Autonomous Operation 323
- 9.4.4 Applicability of Spectroscopic Methods in Continuous Biomanufacturing 328
- 9.4.5 Proposed Control Strategy Including PAT 332
- 9.4.6 Evaluation and Summary of PAT 337
- 9.5 Conclusion 338 Acknowledgments 339 References 339

## 10 Regulatory and Quality Considerations of Continuous Bioprocessing 351

Britta Manser and Martin Glenz

- 10.1 Introduction 351
- 10.2 Integrated Processing 352
- 10.3 Process Traceability 353
- 10.3.1 Batch and Lot Definition 353
- 10.3.2 Lot Traceability and Deviation Management 354
- 10.4 Process Consistency 355
- 10.4.1 Process Control 356
- 10.4.1.1 Automation 356
- 10.4.1.2 Process Analytical Technologies (PAT) 357
- 10.4.1.3 Data Analysis 359
- 10.4.1.4 Real-Time Release Testing 360
- 10.4.2 Quality by Design 360
- 10.4.2.1 Multicolumn Protein A Chromatography 361
- 10.4.2.2 Continuous Virus Inactivation 362
- 10.4.2.3 Bind/Elute Cation Exchange Chromatography 362
- 10.4.2.4 Flow-Through Anion Exchange Chromatography 363
- 10.4.2.5 Ultrafiltration and Diafiltration 363
- 10.4.2.6 Sterile Filtration 363
- 10.4.2.7 Virus Reduction Filtration 363

xii Contents

10.4.2.8	Connection of Unit Operations 364
10.5	Patient Safety 365
10.5.1	Contamination Control 365
10.5.2	Virus Safety 366
10.5.2.1	Virus Reduction in Chromatography 367
10.5.2.2	Low-pH Virus Inactivation 367
10.5.2.3	Virus Reduction Filtration 368
10.6	Equipment Design 369
10.7	Conclusion 370
	References 371

Index 377

## Preface

During the past two decades, we have seen great trends in the advancements of technologies especially in accelerating the bioprocessing sector for manufacturing. The current Covid-19 pandemic and the currently existing bioprocessing technologies have been accelerated to meet the global needs of vaccines. One of the several issues that the current pandemic has highlighted is the need to be in the forefront to quickly meet the global market demand. The requirements to bring vaccines to the market and scale up the production at a much higher speed have accelerated the research and development. Clinical trials and supply chain strategies were carried out with their established processes. The rapid development of vaccines has set a positive precedent and the ongoing expectation that biological products will continue to reach the market much faster than in the past. The pandemic has certainly disturbed the equilibrium, and hence, Pharma 4.0 is underway.

Over the past ten years, pharmaceutical industries have adopted continuous processing and have invested to manufacture the products economically, to ease the method of operation, and to minimize the operational cost.

Process intensification is an ongoing trend in the bioprocessing sector that focuses on continuous bioprocessing. Over the years, industries have been regularly adapting process intensification methods.

This book presents the current advances in the intensified bioprocessing process and its application in biomanufacturing. Each chapter brings out detailed information and its values in the bioprocessing sector.

We hope that this volume will stimulate great appreciation of the usefulness, efficiency, and its potential in continuous processing of biological products and propel further progress in advancing continuous processing to meet the ever-increasing challenges and demands in the manufacturing of therapeutic products.

This book has been completed with the help and support of my friends and colleagues. It is a great pleasure for me to acknowledge the authors with deep gratitude for their contribution toward the chapters and for spending their valuable time. During this Pandemic period, one of the contributors and his family has unfortunately been the victim, and I would like to sincerely thank him and his family for still completing the chapter.



Finally, I would like to thank Felix Bloeck, Sakeena Qurashi of Wiley, and their team for their great encouragement and support throughout the preparation of this book.

Maidenhead 19 April 2021 Ganapathy Subramanian

Part I

**Continuous Biomanufacturing** 

|1

#### 1

# Strategies for Continuous Processing in Microbial Systems

Julian Kopp<sup>1</sup>, Christoph Slouka<sup>2</sup>, Frank Delvigne<sup>3</sup>, and Christoph Herwig<sup>1,2</sup>

<sup>1</sup>Vienna University of Technology, Institute of Chemical, Environmental and Biological Engineering, Christian Doppler Laboratory for Mechanistic and Physiological Methods for Improved Bioprocesses, 1060, Vienna, Austria

<sup>2</sup> Vienna University of Technology, Institute of Chemical Environmental and Bioscience Engineering, Research Division Biochemical Engineering, Department of Chemical, Environmental and Biological Engineering, Gumpendorferstr. 1a, 1060, Vienna, Austria

<sup>3</sup> University of Liège, Terra Research and Teaching Center, Microbial Processes and Interactions (MiPI), Gembloux Agro-Bio Tech, Département GxABT, Bât. ABT09 G140 - Microbial, food and biobased technologies, Avenue de la Faculté d'Agronomie 2B, 5030, Gembloux, Belgium

# 1.1 Introduction

#### 1.1.1 Microbial Hosts and Their Applications in Biotechnology

With regard to microbial cultivation technology, first associations might be drawn between classical food technological applications like ethanol fermentation in beer and wine and production of dry yeast for baking dough. Nevertheless, microbial systems play a fundamental role in all parts of biotechnology in a multitude of industrially used processes. Table 1.1 gives a – certainly not complete – list for possible application of microbes in today's industrial biotechnology.

There is a high variety of possible applications for a high number of different microorganisms (MOs) as shown in Table 1.1. There are classical working horses like *Escherichia coli*, *Saccharomyces cerevisiae*, and *Bacillus* spp. that can be cultivated easily to high cell densities and produce high amounts of the desired product. Other applications and microorganism suffer from inhibitory effects (e.g. inhibition from contaminants in waste water) and low biomass and product yields. Continuous cultivations are referred to increase the time–space yield (TSY) of many processes and provide optimal usage of installed assets. Still, most these processes are established for biomass generation or detoxification. Only very few continuously operated processes involve the production of recombinant compounds. The benefits and drawbacks of continuous cultivation will be discussed throughout this book chapter, focusing especially on microbial hosts. Hence, the ideal cultivation mode must be chosen wisely.

Process Control, Intensification, and Digitalisation in Continuous Biomanufacturing, First Edition. Edited by Ganapathy Subramanian. © 2022 WILEY-VCH GmbH. Published 2022 by WILEY-VCH GmbH.

### Table 1.1 Applications of microbial biotechnology.

Microbes	Benefit	Application in biotechnology	Cultivation mode	Source
Aspergillus niger, Enterobacteria	Overproduction of raw chemical by MOs, e.g. citric acid, lactic acid, vitamins	Bulk chemicals	Batch, fed-batch, and continuous cultivations	[1-3]
Thermophilic microbes – genera Picrophilus, Thermoplasma, Sulfolobus	High-temperature stable enzymes	Food, feed, textile, chemical, pharmaceutical, and other industrial sectors	Continuous cultivation	[4, 5]
Thiobacillus/ Leptospirillum	Noble metal recovery	Bio-oxidation	Bioleaching	[6]
High diverse group, e.g. <i>R. eutropha</i>	Conversion of toxic organic compounds, surface binding of heavy metals	Bioremediation	Batch and continuous processing	[7, 8]
E. coli, Bacillus, S. cerevisiae, P. pastoris	Drug production, antibiotics, etc.	Biopharmaceutical industry, enzyme industry, agricultural industry	Fed-batch technology	[9, 10]
Lactobacillus and Bifidobacterium	Functional food	Probiotics	Batch cultivation	[11]
S. cerevisiae, Zymomonas mobilis, Klebsiella oxytoca, Streptococcus fragilis	Biomass fuels based on waste streams	Biofuels	Batch and continuous cultivations	[12, 13]
Wild type: Ralstonia eutropha, Alcaligenes latus; Recombinant: Aeromonas hydrophila, E. coli Photosynthetic: Synechocystis sp.	Environmentally friendly non- petrochemical- based plastics	Bioplastics (polyhydroxyalka- noates)	Batch and fed-batch cultivation	[14, 15]
Haloferax mediterranei, other halophiles	Tolerate high salt concentrations	Detoxification in chemical waste streams	Continuous cultivation	[16, 17]
High diverse groups – depending on application	Waste to value	PHA production; enzymes/organic acids	Batch and fed-batch cultivations	[18, 19]
Mixed cultures, e.g. Proteus vulgaris, Rhodoferax ferrireducens, Geobacter sulfurreducens	Energy generation from waste	Microbial fuel cells	Batch and continuous cultivations	[20]

#### 1.1.2 Regulatory Demands for Their Applied Cultivation Mode

The batch definitions in continuous manufacturing, preciously defined for mammalian cultivations, apply for microbial processes as well: "A Batch means a specific quantity of a drug or other material that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture. In the case of a drug product manufactured by a continuous process, it is a specific identified amount produced in a unit of time or quantity in a manner that assures its having uniform character and quality within specified limits" 21 CFR 210.3 2, or "a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval" EU GMP Guide, Part II (ICH Q7).

More important than batch definition is the application of the quality-by-design (QbD) context to continuous processing. Generally, QbD mainly urges to relate critical quality attributes (CQAs) to critical process parameters (CPPs) and raw material attributes (RMA) to form a design space [21]: "A multidimensional combination and interaction of input variables and process parameters that have been demonstrated to provide assurance of quality of the product" for demonstrating process understanding. As proposed by current validation guidelines [22], stage 1 validation includes the execution of process characterization studies (PCS), which is the "collection and evaluation of data, from the process design stage throughout production. This establishes scientific evidence that a process is capable of consistently delivering quality product." PCS finally leads to the awareness of the mutual interplay of CPPs on CQAs. This demonstrates process robustness within multivariate normal operating ranges (NOR) and therefore finally proposes the control strategy including process and analytical controls. Currently, this is achieved by fusing development and manufacturing data.

Using an enhanced PCS approach, the determination of appropriate material specifications and process parameter ranges could follow a sequence such as the following [23]:

- (i) Identify potential sources of process variability.
- (ii) Identify the material attributes and process parameters likely to have the greatest impact on drug substance quality.
- (iii) Design and conduct studies (e.g. mechanistic and/or kinetic evaluations, multivariate design of experiments, simulations, modeling) to identify and confirm the links and relationships of material attributes and process parameters to drug substance CQAs.
- (iv) Analyze and assess the data to establish appropriate ranges, including the establishment of a design space.

Even more, continuous processes require a different level of process understanding: as an example, classical recombinant protein production (RPP) using *E. coli* as a host pools the product solution after four days of processing. The time-variant dependency of CPPs and CQAs is finally integrated in one analytical result, and the process is also registered as such. Hence, batch processes are characterized by operating subsequent steps on the *integral* outcome of the current process step. Implementing

#### 6 1 Strategies for Continuous Processing in Microbial Systems

continuous operations, we must *understand the time dependency* between CPPs and CQAs with the goal to have a time-invariant CQA process result. Hence, as microbial processes are more dynamic in terms of kinetics and stoichiometry, proper understanding of a dynamic design space and establishment of a robust control strategy are more relevant from a regulatory point of view ("A planned set of controls derived from product and process understanding that assure process performance and product quality") [21].

For continuous processing, time-variant interrelations between CPPs and CQAs must be transformed into a control concept. This calls for the enhanced use of metabolic and kinetic models integrated in experimental designs for elucidating the design space. Of course, initially, we relate CPPs and CQAs in a classical QbD manner. However, we need to enhance this context: for example, classical design of experiment (DoE) approaches can only capture the response of the system to time-invariant factors of the integral experiment. For continuous operation, and in contrast to conventional development strategies, we aim to operate with time-invariant process variables and COAs. Therefore, we need to understand the time-variant dependencies on their CPPs for control. Thus, we do not change the CPPs to analyze the integral outcome of the CQAs, but we change the CQAs to analyze the integral outcome of the CPPs, which can compensate for their variability of time. Hence, the development strategy is enhanced. We may need dynamic model-based experimental designs to develop a control strategy able to cope with process variability over time; those experimental setups need to be established in the R&D environments [24].

Hence, continuous processing requires a *much earlier definition of the process control strategy directly during the process development and characterization phase.* We need this control strategy earlier as prerequisite for process design. NORs must be defined earlier and turned into a real process control strategy based on PAT, models, and controls. Hence, the tasks of PCS need to be done already during the development. Those elements may include data mining, risk assessments, characterization of process performance, screening studies, criticality assessment [23], and integrated process modeling [25], as shown in the workflow in Figure 1.1. On the other hand, scale-down model qualification tasks may not be necessary, as the development scale may already be the production scale, since productivity is scaled by processing time or scale-out techniques.

Thus, R&D labs need therefore higher data management and data science orientation, as well as advanced PAT and process control environments as skill set, which will be addressed in Chapter 3.

# **1.2** Overview of Applied Cultivation Methods in Industrial Biotechnology

As an easy rule, the cultivation mode resulting in the highest TSY should be pursued. TSY could be defined in pharmaceutical applications as the highest throughput from pre-culture inoculation until purified drug substance, in gram product per operating





liter per day [26], or for waste streams as the process enabling the highest catalytic capacity to degrade toxic compounds.

#### 1.2.1 Batch and Fed-Batch Cultivations

#### 1.2.1.1 Conventional Approaches and Their Technical Limitations

The golden standard in RPP is batch and fed-batch cultivations. With regard to batch, all ingredients are added to the reactor, and microorganism react until limiting component inhibits further growth. Common limitation elements in industrial biotechnology are carbon, nitrogen, or phosphor. Problems in batch cultivation are that MOs grow at maximal specific growth rate and causing problems in aeration and heat transfer, discussed in more detail later. This limits the maximal limiting component concentration and results in low overall biomass concentrations. For this purpose, fed-batch technology is currently applied. Additional feeding is conducted (e.g. high concentrated sugar feeds), which results in higher biomass concentrations. Controlled addition of limiting substrate can also overcome several problems like carbon catabolite repression and substrate inhibition [27]. High cell density cultivations are referred to increase the overall titer. However depending on the media and reactor setup employed, biomass concentrations should not exceed physiological levels [28]. This is because in high cell density fermentations, (i) non-controlled nutrient limitation might occur, (ii) K<sub>L</sub>a levels might not cope for the demands of high cell densities, and (iii) reactor cooling capacity might be exceeded [29]. To cope for demands of limited oxygen transfer, additional oxygen could be supplemented, but at industrial scale, additional oxygen supply might lead to unfeasible cultivation costs. pO2-limited cultivations tend to increase secondary metabolite production to synthetize their needed reduction equivalents. Furthermore, amino acid mis-incorporation in recombinant produced proteins has been found as a side effect of oxygen-limited cultivations [30, 31]. Moreover, biomass concentrations must be kept within the reactor cooling capacity. High growth rates monitored for many microorganism can cause high heat formation, being especially a problem in yeast fermentation: as methanol is commonly used for the induction in Pichia pastoris systems containing alcohol oxidase (AOX) promoters, high heat is generated by methanol on its own [32]. To stay within reactor cooling 1 Strategies for Continuous Processing in Microbial Systems



**Figure 1.2** General procedure for microbial Fed-batch cultivations: A Batch phase is followed by a non-induced Fed-batch phase and an Induction phase, with  $q_{s,C}$  being the specific carbon uptake rate, with V being the reactor volume and CO<sub>2</sub> coding for residual carbon dioxide.

capacities, the Mut<sup>S</sup> strain was invented, showing decreased methanol uptake rates in *P. pastoris*. Hence a compromise between maximum biomass concentration and reactor cooling capacity must be made at an industrial level.

#### 1.2.1.2 Feeding and Control Strategies Using E. coli as a Model Organism

A sketch for industrial fed batch used for *E. coli* cultivation in red biotechnology is shown in Figure 1.2. Maximum specific feeding rates  $(q_{s,max})$  are generally applied through batch. Fed batches are operated at specific feeding rate values far below the

 $q_{s,\max}$ 

The batch phase is followed by an exponential fed batch for biomass production according to

$$F(t) = \frac{q_{s,(C)} * X(t) * \rho_f}{c_f} \text{with } X(t) = X(t=0) * e^{\mu * t}$$
(1.1)

where F is the feeding rate (g/h),  $q_{s(C)}$  is the specific uptake rate (g/g/h), X(t) is the absolute biomass at the time point t (hours),  $\rho_F$  is the feed density (g/l),  $c_F$  is the feed concentration (g/l), X(t = 0) is the biomass before start of the fed batch in (g), and  $\mu$  is the specific growth rate (1/h). After the first exponential fed-batch phase, cells are induced for RPP and fed until harvest. Besides the classic exponential fed batch, different feeding profiles can be employed, which is often done throughout induction phase [33, 34]. Cells are mainly grown carbon limited after batch phase, as a desired specific growth rate ( $\mu$ ) can be adjusted easily, with a set  $\mu$  beneath  $\mu_{max}/2$  to reduce acetate formation and reduce stress onto host cells. Common control strategies for carbon-limited growth are either basic feed-forward protocols (see Eq. (1.1)) or soft-sensor approaches [35]. Throughout feed-forward control strategies, a constant  $q_s$  value is set for a fixed timeframe to achieve a targeted biomass within a certain time. The amount of fed carbon is calculated into biomass, assuming a constant biomass yield. As overall biomass is increasing, feed rate is thus increased via higher pump set points, which are adjusted using a PID controller (proportional, integral, and derivative control terms). However, in this strategy, no feedback control is implied. In soft-sensor approaches, a feedback loop to off-gas signals by mass balancing is implemented in the feeding strategy. Hence, feeding rate can be adjusted

8

to unexpected process deviations. The usage of a noncontrolled feeding strategies might lead to substrate accumulation in carbon-limited feeding approaches. Off-gas signals are used to predict biomass formations due to the stoichiometric balances, hence adjusting pump set points [26, 36].

#### 1.2.2 Introduction into Microbial Continuous Biomanufacturing (CBM)

#### 1.2.2.1 General Considerations

In some branches of biotechnology, continuous processing is already established (i.e. bioleaching and oxidation, using several stirred tank reactors serially connected) [6]. Also in the field of biofuels, the trend leads to a continuous production platform [37, 38]. Moreover, continuous processing is well suited for the degradation of toxic compounds. As cell growth-inhibiting compounds are fed, growth rates can be very low, and thus retentostat setups (Figure 1.3b) can increase the detoxification efficiency as shown for the halophile Haloferax mediterranei [16]. Large-scale detoxification can be found in wastewater treatment plants, also using retentostat principles. Retentostat cultivation used a retention device (i.e. 0.2 µm pore size membrane) to maintain a controlled number of cells in the cultivation device. Hence, a feed/bleed system can be maintained at feasible cell densities compared with common chemostat cultivation, especially advantageous for slow-growing organisms. Problems such as changing media composition and changing yields and inhibitory substances often make continuous cultivations challenging in diverse branches. For recombinant protein expression, using microbial hosts, continuous biomanufacturing (CBM) is still far from its industrial application. Despite the several benefits coming with fed-batch cultivation, product quality is highly time dependent. Furthermore, high batch-to-batch variations may result in severe problems in the subsequent downstream process for red biotechnology. The following benefits could be expected from the establishment of CBM for microbial cultivations:

- Small reactor systems reduce investment costs and enable efficient and highly flexible production even for small companies ("small footprint facilities").
- Cleaning in place (CIP) and steam in place (SIP) can be reduced to a minimum, as cultivation times are increased from some days to several weeks, making this cultivation mode **sustainable**.
- Quality of the product is not batch performance dependent but can be expressed at **constant quality**.
- Continuous waste streams may be used for certain applications (whey from milk industry, molasses from sugar industry, etc.). This would decrease the costs for the product drastically, leading to **circular economy** approaches.
- Continuous upstream enables continuous downstream, leading to an **integrated process**, and enables robust downstream processing, e.g. usage of "simulated moving bed chromatography."

In this chapter, three different cultivation modes that are often implemented in the upstream processing (USP) of microbial continuous systems will be discussed. Figure 1.3a) shows the classic chemostat process for microbial systems. A feed is



**Figure 1.3** (a) Classical microbial chemostat for fast-growing organism. Feed is pumped at a fixed dilution rate and bled out at a certain volume including the product. (b) Cell retention system for slow-growing microorganism. Cell concentrations are increased until the theoretical biomass to substrate yield is reached. Product is usually concentrated after (c) Cascade systems for sequential/serial addition of bioreactors. First reactor is used for biomass production only, biomass is transferred from reactor 1 to reactor 2 indicated by the blue line. Only reactor 2 is fed with an induction feed and bleed out of reactor 2 is containing target product. This cultivation system could be used for different MOs digesting the same feedstock or for recombinant protein production. Source: Refs. [39–41].

added at a constant rate to the reactor. The bleed is removed using pneumatic valves, connected to peristaltic pumps, enabling constant volume throughout cultivation. This system is preferably used for fast-growing MOs. The main benefit is easy process control as generally only monitoring is necessary and no control circuits need to be used, like PI or PID controllers.

Retentostats, also called perfusion systems, shown in Figure 1.3b), contain a common chemostat setup with an additional hollow fiber membrane to retain cells in the reactor. Pumps (feed, bleed, cell retention) must be adjusted accordingly to guarantee a stable process performance. Retentostats are common for slow-growing cultures and are therefore often used in cell culture. The second advantage is that extracellular product can easily be harvested using cell retention modules

and waste-to-value approaches can clear contaminants effectively through higher biomass concentrations inside the reactor. The third cultivation system is shown in Figure 1.3c, which is regarded as a serial combination of chemostats or retentostat systems. Cascaded cultivation systems can be successfully applied for red biotechnology approaches in decoupling biomass production from induction of the cells in a spatially resolved manner [39, 40] (see Section 1.4.3). Hereby cells in reactor one is grown "burden-free," whereas the second reactor is operated in an induced stage. Continuous application is given as two feed/bleed systems are serially connected with each other: feed, free of inducer, is supplemented to the burden-free stage (first reactor), and non-induced biomass is transferred to the induced reactor (second reactor). Further ongoing, the second reactor is supplied with an inducer-containing feed to initiate RPP [40]. Using this system, the benefits of time-dependent cultivations can be included in a continuous system as (i) burden-free cell growth, equal to non-induced biomass growth, can be maintained in the first stage and (ii) adequate induction times can be set via the residence time in the induced stage. Cascaded or serial combinations can also be used in waste-to-value approaches and circular economy thoughts combining aerobic cultures producing CO<sub>2</sub> that may be recycled in the second reactor using autotroph/chemolithotroph MOs [39], implementing a neutral carbon footprint.

The cultivation method of choice has of course always to be adapted to the current aim. A rough overview about the desired aim can be gained via proper mass balances.

#### 1.2.2.2 Mass Balancing and the Macroscopic Effects in Chemostat Cultures

Mass balancing can be perfectly used to highlight benefits of a continuous system in favor of the classical fed-batch approach. The general macroscopic mass balance for an ideal stirred tank reactor is given in Eq. (1.2):

$$\dot{V}_{in} * c_{i,in} + \dot{V}_{out} * c_{i,out} + V_R * r_i = V_R * \frac{\partial c_i}{\partial t} + c_i * \frac{\partial V_R}{\partial t}$$
(1.2)

where  $\dot{V}_{in}$  is the volume flux in the reactor,  $\dot{V}_{out}$  is the flux of the bleed,  $c_{i,in}$  is the concentration of component *i* in the influx,  $c_{i,out}$  is the concentration of component in the bleed,  $V_R$  is the reactor volume,  $r_i$  is the reaction rate for component *i*, and *t* is the time. As one of the strong benefits of continuous reactor systems is the time independence of the reactor upon tuning, the balance reduces to

$$\dot{V}_{in} * c_{i,in} + \dot{V}_{out} * c_{i,out} = -V_R * r_i$$
 (1.3)

As flux in and flux out are constant in a classic chemostat and solving for the reaction rate and substituting  $\frac{\dot{V}}{V_R} = D$ , with *D* being the respective dilution rate in 1/h,

$$r_i = \Delta c_i * D \tag{1.4}$$

It is clearly visible that every volumetric rate  $r_i$  is dependent upon the applied dilution rate of the bioreactor and on the concentration of components in the media. TSY, being the volumetric productivity, is directly dependent on these two

#### **12** 1 Strategies for Continuous Processing in Microbial Systems



**Figure 1.4** (a) A set point for stable biomass production was chosen, all fed substrate is consumed, and biomass is formed based on the yield coefficient. Upon induction, the  $Y_{X/S}$  changes, and less substrate can be metabolized. (b) shows that the stable set point before might now suffer from a decrease in yield. Hence sugar biomass formation might be reduced at the given set point, and substrate is accumulating.

factors. Consequently, high dilution rates and high concentrations of the limiting component in the feed should positively influence the TSY. Connections between the different rates can be easily drawn in using yield coefficients in Eq. (1.5):

$$Y_{\frac{a}{b}} = \frac{r_a}{r_b} \tag{1.5}$$

Postulating constant yield coefficients, the continuous reactor can be set up and operated at optimal conditions. In general, this hypothesis holds true for chemostats with defined media of constant quality and sole biomass production. However, in RPP using, for example pET plasmids, induction with isopropyl- $\beta$ -Dthiogalactopyranosid (IPTG), lactose or related inducer is necessary. The effects of induction onto the cell itself will be discussed in a later chapter. We regard the reactor as a black box for now and just look at the effects of a changing substrate to biomass yield ( $Y_{X/S}$ ). A visualization is given in Figure 1.4.

Starting with induction feeds at identical carbon concentrations, the yield coefficient changes within some hours as several stress responses affect cell growth. With decreasing yield, the same set point of dilution rate might possibly lead to sugar accumulation. As the stable set point moves toward the washout regime and consequently biomass concentrations are reduced, substrate is washed out of the reactor. This is no stable process and brings again a time dependence of the yield coefficient into consideration. These effects act also upon productivity and make single-vessel chemostat cultures very unstable at fast-growing MOs.

Similar problems are observed upon changes in the feed substrate quality. These changes may be based on fluctuations in substrate concentration but could also be fluctuating in inhibitory substances. Simple Michaelis–Menten kinetic considerations show effects upon the process in Eq. (1.6). We assume competitive inhibition as cells are directly affected by the inhibitory substance in the reactor:

$$\mu = \mu_{\max} * \frac{[S]}{[S] * K_S * (1 + K_I * [I])}$$
(1.6)

where  $\mu$  is the specific growth rate, which is identical to the dilution rate, [S] is the substrate concentration,  $\mu_{max}$  is the maximal possible growth rate,  $K_S$  is the reaction

constant for substrate uptake, [I] is the inhibitor concentration, and  $K_I$  is the reaction constant for the inhibitory reaction. Therefore, changing inhibitory concentrations [I], as well as substrate concentrations [S], has effects on the specific growth rate and may shift the critical specific growth rate. Close to  $\mu_{max}$ ,  $\mu = D$  is not valid anymore, as washout starts and hence results in an unstable process.

So even simple macroscopic mass balance and kinetic considerations, considering the biomass in the reactor, show the complexity of the system. Further cell physiological effects might occur in RPP. However, the high expression of recombinant protein and the extremely high doubling rates may make microbial continuous cultivation a promising alternative to state-of-the-art fed-batch approaches.

#### 1.2.3 Microbial CBM vs. Mammalian CBM

#### 1.2.3.1 Differences in Upstream of Microbial CBM Compared with Cell Culture

The first remarkable difference between microbial and cell culture-based expression systems are the differences in cell doubling times. While cell culture-based cultivations take up several hours for a cell division, the maximal doubling time in *E. coli* can be 20 minutes. Table 1.2 compares the three most important organisms regarding their growth rates upon the production of recombinant proteins. Absolute values may differ from strain to strain and expressed recombinant protein but give a certain lead to compare different continuous approaches.

Cell cultures (Chinese hamster ovary [CHO] cells) exhibit exceptionally low doubling rates (13.8–85 hours per cell doubling). This also results in long preparation times for pre-cultures (seed flasks) up to four weeks and the starting batch phase before enabling continuous feeding. For *E. coli* preparation, pre-culture and batch phase take approximately 30 hours, depending on applied sugar concentrations [35, 46]. It was already stated that microbial systems show very high dynamics in metabolism and recombinant protein expression, based on the high number of cell divisions during a continuous process [44]. Taking mean dilution rates in Table 1.1 and comparing generation times to one week of cultivation, which corresponds to 168 hours, CHO cells doubled in mean 4.3 times, *E. coli* cells doubled 50 times, and *P. pastoris*, as frequently used expression host for yeast-based expression, doubled 18.5 times.

While CHO and yeast cells have a eukaryotic translation and posttranslational modification (PTM) mechanism (through golgi apparatus), prokaryotic

Organism	Growth rate (1/h)	General process duration (h)	Generations (–)	Source
CHO cells	0.0008-0.05	650-2160	2–47	[42, 43]
E. coli	0.1-0.49	up to 300 h	43-212	[39, 44]
P. pastoris	0.009-0.2	up to 1000 h	13-290	[44, 45]

**Table 1.2** Growth rates and approximated generations for cultivation times found in the literature.

Source: Refs. [23, 27, 28, 33].

#### 14 1 Strategies for Continuous Processing in Microbial Systems

microorganism lack these systems [47, 48]. As the product is generally secreted into cultivation supernatant, cell culture processes rely mainly on retentostat/perfusion technology, where product can be harvested in the broth, without dealing with the intact host cell. Yeasts also have the possibility to translocate the product to the broth while having a sufficient high growth rate. Recombinant proteins produced in yeast, however, are highly mannose glycosylated, and no human like N-glycosylation can be performed. Hence, products need cost- and time-intensive treatment prior to clinical application [49]. Recombinant proteins in *E. coli* are located primary inside the cell. Most of these products are expressed in the cytoplasm and kept in this place, where no signal sequences for transport into the periplasm are attached to the protein. The reducing milieu in the cytoplasm does not allow disulfide bond creation and makes correct folding of complex proteins difficult. The result is often the expression of inclusion bodies (IBs), misfolded proteins with hydrophobic character. Hence, continuous purification in microbial systems might be leading to challenging technical applications, owing to different product loci.

#### 1.2.3.2 Downstream in Microbial CBM

An integration of the process from up- to downstream would be the desired future perspective in a modular design. This would ease the way for "small-footprint facilities" as high modular elements can be easily exchanged and stuck together for a new product. Furthermore, costs can be strongly reduced especially in the downstream, heading toward smaller columns [50–52]. Continuous purification methods for extracellular proteins have been established [53]. Filtration steps, followed by continuous chromatography systems (making use of simulated moving bed principles), have been established for the purification of products derived from mammalian cells [51].

However, other downstream unit operations, especially such operations for intracellular proteins, are still considered problematic. Figure 1.5 shows the schematic downstream chain for intracellular proteins and highlights the additional steps needed for misfolded protein aggregates derived by *E. coli*, which are known as IBs.



**Figure 1.5** Simplified process chain for production of a recombinant product in *E. coli*. Green unit operations can be accessed in a continuous mode; red operations are hard to realize. IBs need at least two additional steps during downstream.